La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Hitek Global a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Hitek Global..

Hitek Global (NASDAQ:HKIT) Azioni, Catena delle Opzioni

Hitek Global

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.

Hitek Global Inc. - Class A Ordinary Share

Hitek Global Inc

<ul>
<li>Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer's Disease.</li>
<li>Company receives expanded access protocol authorization from the U.S. Food and Drug Administration (FDA) for troculeucel granted to treat patients with known diagnoses of multiple neurodegenerative diseases.</li>
<li>IND approval allows for up to 20 patients to be enrolled; first patient enrollment is anticipated in Q3 2025. &nbsp;</li>
</ul>
SANTA ANA, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#OTC">NKGN</a>) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access Program (EAP) authorization for its IND for an open-label, non-randomized, multi-center intermediate size expanded access protocol for use of troculeucel for neurodegenerative diseases. This includes its use for the treatment of several neurodegenerative diseases, many of which currently have no effective therapy.
While NKGen's ongoing double-blind randomized Phase 2a trial is focused on moderate-stage Alzheimer's disease (NCT06189963), this EAP IND marks the company's exploration into the treatment of other less common neurodegenerative diseases. In addition to earlier stage Alzheimer's Disease (AD), this IND includes the treatment of Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal degeneration (CBD), Multiple Sclerosis (MS) and Lewy Body Dementia (LBD).
This IND approval will allow NKGen to expand and explore the use of troculeucel in up to 20 patients.

Biotech

News

General

NKGN

NKGen Biotech Receives FDA Expanded Access Approval To Treat Multiple Neurodegenerative Diseases With Troculeucel

Truist Securities analyst Patrick Scholes downgrades Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) from Buy to Hold and raises the price target from $275 to $337.

Downgrades

Price Target

Analyst Ratings

Truist Securities Downgrades Royal Caribbean Gr to Hold, Raises Price Target to $337

JMP Securities analyst Devin Ryan maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Market Outperform and raises the price target from $106 to $110.

SCHW

JMP Securities Maintains Market Outperform on Charles Schwab, Raises Price Target to $110

First United (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUNC#NASDAQ">FUNC</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.84 by 9.52 percent. This is a 22.67 percent increase over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $21.65 million which beat the analyst consensus estimate of $21.26 million by 1.83 percent. This is a 8.13 percent increase over sales of $20.02 million the same period last year.

Earnings

FUNC

First United Q2 EPS $0.92 Beats $0.84 Estimate, Sales $21.65M Beat $21.26M Estimate

Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>), a global industrial technology company and leading provider of sensors, sensor-rich solutions and electrical protection devices used in mission-critical systems to help its customers address increasingly complex engineering and operating performance requirements, today announced that Andrew Lynch has been named as Sensata's Chief Financial Officer, effective immediately. Mr. Lynch assumes leadership and oversight of Sensata's global financial activities.

Management

CORRECTION: Sensata Technologies Appoints Andrew Lynch As CFO

Enrollment in FURVENT was completed in Q1 2025
Firmonertinib received FDA Breakthrough Therapy Designation in this patient population

AVBP

ArriVent Projects Topline Phase 3 FURVENT Data For Firmonertinib In First-Line NSCLC EGFR Exon20 Insertion Mutations In Early 2026

Guidance

GMED

Globus Medical Reaffirms FY25 Revenue Guidance Of $2.80B - $2.90B And Non-GAAP EPS Of $3.00 - $3.30

JMP Securities analyst Mitch Germain initiates coverage on Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) with a Market Outperform rating and announces Price Target of $17.

Initiation

NMRK

JMP Securities Initiates Coverage On Newmark Group with Market Outperform Rating, Announces Price Target of $17

Globus Medical, Inc. also announced today its preliminary sales results for the second quarter ending June 30, 2025. The Company anticipates second quarter 2025 sales to be approximately $745.3 million, an as-reported increase of 18.4% over the second quarter of 2024. Base business sales, excluding the contribution from the recently acquired Nevro, Inc., are expected to be approximately $650.8 million, an as-reported increase of 3.3 percent over the second quarter of 2024. On a day-adjusted basis, base business sales increased approximately 4.8 percent over the prior year quarter.

Globus Medical Expects Q2 Sales To Be ~$745.3M, As-Reported Increase Of 18.4% Over Q2 2024

&nbsp;
Increases&nbsp;Ethereum treasury holdings to approximately $38 million, with recent $30 million purchase
Launches NFT yield program creating one of the first treasury management strategies to leverage digital assets within the&nbsp;Ethereum ecosystem targeting an expected annualized return of 6%-10%
FRISCO, Texas, July 21, 2025 /PRNewswire/ -- &mdash; GameSquare Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>) (the &quot;Company&quot; or &quot;GameSquare&quot;) a next-generation media, entertainment, and technology company, today announced that its Board of Directors has increased the Company&#39;s digital asset treasury management authorization from $100 million to $250 million.&nbsp;
As part of the expanded program, the Board has approved a new NFT yield strategy, with an initial $10 million allocation. The updated treasury framework enables the Company to actively deploy capital into high-quality Ethereum-based assets and generate sustainable stablecoin yields targeting a 6&ndash;10% return.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

GAME

GameSquare Expands Digital Asset Treasury To $250M, Boosts Ethereum Holdings To ~$38M And Launches NFT Yield Strategy Targeting 6-10% Returns

JMP Securities analyst Mitch Germain initiates coverage on Marcus &amp; Millichap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMI#NYSE">MMI</a>) with a Market Perform rating.

JMP Securities Initiates Coverage On Marcus & Millichap with Market Perform Rating

ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) ("ECARX" or the "Company"), a global mobility technology provider, today announced that it has received ISO9001 (Quality Management Systems), ISO14001 (Environmental Management Systems), and ISO45001 (Occupational Health &amp; Safety) certifications, covering the entire life cycle from designs to sales of intelligent cockpit and intelligent driving solutions. This underscores ECARX's commitment to and long-term investment in developing safe and efficient intelligent solutions for automakers globally as it accelerates its global strategy.
ISO certifications are internationally recognized as a prerequisite for collaboration with leading automakers around the world. By upholding these standards across design, development, manufacturing, delivery and after-sales support, ECARX is building a solid foundation with the highest international standards across every aspect of its operations to serve automakers and support vehicle deployment globally.
These internationally recognized certifications remove potential barriers to entry in developed markets where stringent quality, environmental, and safety standards are required to be met by suppliers. For ECARX, whose solutions are already powering over 8.7 million vehicles worldwide, these certifications create a clearer path to integration with global automotive platforms and strengthen its competitive positioning when bidding on new projects.
The new certifications build on ECARX's existing portfolio of quality, functional-safety and information-security accreditations—credentials that collectively differentiate the Company in the competitive automotive-tech landscape.&nbsp;As ECARX continues to expand its global customer base and extends its technology stack into AI, robotics and embodied-intelligence applications, these ISO certifications will also underpin future product releases beyond the automotive sector.

ECARX Achieves Key ISO Certifications, Strengthening Global Expansion And Automotive Partnership Opportunities

Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice President of Finance, has been appointed Senior Vice President and Chief Financial Officer.

Globus Medical Appoints Keith Pfeil As President And CEO, Effective July 18, 2025, Succeeding Daniel Scavilla

Truist Securities analyst Danielle Brill initiates coverage on Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy rating and announces Price Target of $86.

IRON

Truist Securities Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $86

Dragonfly Energy Holdings Corp. ("Dragonfly Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>), an industry leader in energy storage and battery technology, today announced that it has entered into a Settlement and Mutual Release Agreement (the "Agreement") with the holder of its Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), eliminating all outstanding shares of the Series A Preferred Stock and associated common stock issuance obligations.
Under the terms of the Agreement, Dragonfly Energy will issue 2,100,000 shares of the Company's common stock, par value $0.0001 per share, in exchange for the surrender of all outstanding shares of Series A Preferred Stock. The transaction satisfies in full the Company's obligations under the Series A Preferred Stock and related agreements.

DFLI

Dragonfly Energy Eliminates Series A Preferred Stock In Exchange For 2.1M Common Shares, Ending Related Obligations

DA Davidson analyst Gary Tenner maintains BancFirst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) with a Neutral and raises the price target from $120 to $136.

BANF

DA Davidson Maintains Neutral on BancFirst, Raises Price Target to $136

WIIM

ProMIS Neurosciences shares are trading higher after the company announced the FDA granted received Fast Track designation to PMN310.

JMP Securities analyst Mitch Germain initiates coverage on Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) with a Market Perform rating.

JMP Securities Initiates Coverage On Jones Lang LaSalle with Market Perform Rating

Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFSA#NASDAQ">PFSA</a>), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it is initiating a Bitcoin treasury strategy via the execution of a Securities Purchase Agreement (the "ELOC") with Ascent Partners Fund LLC, ("Ascent"), pursuant to which Ascent will purchase up to $100,000,000 of the Company's Common Stock. 100% of the net proceeds will be used to purchase Bitcoin (which can be used for debt repayment) provided that the Company's cash balance on the date of the put exceeds $5,000,000.
Under the ELOC the Company will be able to put its shares of Common Stock to Ascent at a price per share equal to 97% of the lowest volume-weighted average price of the Common Stock ("VWAP") in the 5 trading days immediately after each such put. The maximum amount of each put will be lower of $5,000,000 and 100% of the average daily traded value of the Common Stock on the 5 trading days immediately preceding the date of such put.
If the Company's cash balance at the time of any put under the ELOC is less than $5,000,000, the net proceeds shall be allocated first to bring the Company's cash balance to $5,000,000 and the remaining proceeds will be used to purchase Bitcoin, which will serve as the Company's primary treasury reserve asset.&nbsp;
The ELOC will be subject to execution of definitive agreements and customary closing conditions. The number of shares issuable under the ELOC (including the number of shares subject to warrants to be issued to Ascent and described below) will be limited to 19.9% of the Company's number of issued and outstanding shares of Common Stock until shareholders approve the issuance of the total number of shares subject to the ELOC.
In connection with the implementation of the ELOC the Company will issue cashless warrants to purchase 900,000 shares of the Company's Common Stock at an exercise price of $0.01 per share to Ascent.

Comments

Hitek Global

Hitek Global (HKIT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO